CurrentBlue Cross Blue Shield - TennesseePolicy N/A

General Inflammation Testing (CRP and ESR)

This policy governs coverage and reimbursement for measurement of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for diagnosing and monitoring inflammatory conditions for BlueCross BlueShield of Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyGeneral Inflammation Testing (CRP and ESR)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder CRP or ESR only when tied to a diagnosed or suspected inflammatory condition and document the clinical indication.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CRP preferredPreferred biomarker

4Procedure codes listed

ManyIndications listed

Not coveredESR coverage without diagnosis

CRP, ESRPrimary tests

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Medically Necessary Indications

Covered when the following conditions apply

General coverage: Measurement of C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) meets coverage criteria when used for diagnosed or suspected inflammatory conditions as specified in Note 1.

Either conventional or high-sensitivity CRP testing are allowed; when either CRP or ESR are permitted, CRP is the preferred biomarker.

inv-02: Not Medically Necessary / Exclusions

Not covered when

Not covered scenarios: Measurement of ESR for individuals without a diagnosed inflammatory condition; measurement of CRP and/or ESR during a general examination without abnormal findings.

These uses do not meet coverage criteria and will be denied.

inv-03: Indication-specific frequency and test preference

Condition-specific testing preferences and frequency guidance (examples — non exhaustive)

Condition-specific guidance: Lists of conditions with stated test preference and suggested frequency where specified. Examples include: Acute Hematogenous Osteomyelitis — Test Preference = CRP; Frequency = to confirm diagnosis, every 2–3 days early in therapy then weekly until normalization. Rheumatoid Arthritis — Test Preference = CRP or ESR; Frequency = prior to treatment and every 1–3 months during active disease. Hodgkin Lymphoma — Test Preference = ESR; Frequency = every 3–6 months for 1–2 years, then every 6–12 months for 3 years, then annually. Periprosthetic Joint Infection — Test Preference = CRP and ESR; Frequency = not specified. Many other conditions are listed with frequencies varying by disease or marked NS (not specified).

Frequencies are condition-dependent; 'NS' indicates not specified in the source.

inv-04: Guideline-supported indications (informational)

Informational: cited guidelines and studies relevant to appropriate use

Guideline citations: Multiple professional guidelines and studies are cited supporting appropriate use of CRP and ESR across conditions (examples: ACR, EULAR, British Society for Rheumatology, NCCN, NICE, Government of British Columbia guidance, and relevant literature on test performance).

These references provide clinical context; refer to the cited guidelines for disease-specific recommendations.

Measurement of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) is intended to support evaluation or monitoring of a diagnosed or suspected inflammatory condition. Per the policy, ESR measurement for individuals without a diagnosed inflammatory condition does not meet coverage criteria. Likewise, ordering CRP and/or ESR as part of a routine general examination when there are no abnormal findings does not meet coverage criteria. Documentation must link the test order to the clinical indication to establish medical necessity.

Clinicians should be aware of limitations in routine inflammatory testing for specific situations. Published evaluations of diagnostic testing for periprosthetic joint infection indicate that common laboratory tests, including CRP and routine diagnostics, can have a high false-negative rate and results may be influenced by the infecting organism. Similarly, studies comparing CRP and ESR in rheumatologic disease highlight variable agreement and instances where CRP may misdiagnose chronic or low-grade prosthetic joint infections; these limitations should be considered when interpreting results and documenting diagnostic reasoning.

Requests for ESR testing in persons who do not have a diagnosed inflammatory disorder and requests for CRP or ESR obtained during a general physical examination without abnormal signs or symptoms are explicitly stated as not meeting coverage criteria and will be denied unless a documented clinical indication is provided.

The policy notes caution about ordering multiple inflammatory markers in primary care without a clear indication. Evidence and guideline reviews raise questions about the added diagnostic accuracy of routinely ordering multiple markers (CRP and ESR together) for general screening or nonspecific complaints; unnecessary or redundant testing may be discouraged and could risk denial if not clinically justified. Providers should order multiple markers only when the additional test will meaningfully inform diagnosis or management and document that rationale.

Covered Indications and Conditions

inv-26: Multiple inflammatory conditions

Multiple inflammatory conditions with stated test preference and suggested frequency where specified

Condition list (examples): Acute and chronic urticaria — CRP or ESR; frequency: NS. Acute hematogenous osteomyelitis — CRP; frequency: confirm diagnosis, every 2–3 days early then weekly until normalization. Acute phase inflammation — CRP; frequency: NS. Ankylosing spondylitis — CRP or ESR; frequency: regular intervals for active symptoms. Arthritis — CRP and ESR; frequency: 1–3 months initially, then 6–12 months. Castleman’s disease — CRP; frequency: NS. General inflammation — CRP; frequency: NS. Hodgkin lymphoma — ESR; frequency: every 3–6 months for 1–2 years, then every 6–12 months for next 3 years, then annually. Irritable bowel syndrome (to exclude other diagnoses) — CRP and ESR; frequency: at initial assessment. Large vessel vasculitis (giant cell arteritis, Takayasu) — CRP and ESR; frequency: to confirm diagnosis then every 1–3 months first year, every 3–6 months thereafter. Nonradiographic axial spondyloarthritis — CRP or ESR; frequency: regular interval for active symptoms. Polymyalgia rheumatica — CRP or ESR; frequency: at diagnosis and every 3 months during long-term steroid therapy. Periprosthetic joint infections — CRP and ESR; frequency: NS. Rheumatoid arthritis — CRP or ESR; frequency: prior to treatment and every 1–3 months during active disease. Systemic lupus erythematosus — CRP or ESR; frequency: at initial assessment, every 1–3 months during active disease, every 6–12 months during stable disease, and during pregnancy. T-cell lymphomas — ESR; frequency: NS.

This list is illustrative and not exhaustive; many entries in source are marked NS for frequency.

inv-27: Evaluation and monitoring of rheumatologic diseases

Evaluation and monitoring of rheumatologic diseases supported by guideline references

Rheumatologic monitoring: Use of CRP and/or ESR for evaluation and monitoring of rheumatologic diseases (for example rheumatoid arthritis, large‑vessel vasculitis/giant cell arteritis, polymyalgia rheumatica, ankylosing spondylitis) is supported by cited guidelines and literature.

Referenced sources include EULAR, ACR, British Society for Rheumatology and related studies on DAS28-CRP versus DAS28-ESR; refer to those guidelines for disease-specific monitoring intervals and interpretation.

inv-28: Evaluation for suspected periprosthetic joint infection

Evaluation for suspected periprosthetic joint infection — evidence and limitations

PJI evaluation considerations: CRP and ESR are included in evaluation of suspected periprosthetic joint infection, but routine diagnostic tests demonstrate a high false‑negative rate and results may be influenced by the infecting organism; CRP may misdiagnose chronic and low‑grade infections.

Where test limitations exist, document clinical indication and diagnostic reasoning; laboratory results should be interpreted in the context of clinical and microbiologic data.

Frequency Limits and Monitoring Schedules

CRP and/or ESR — condition-specific monitoring frequency

ScopeCRP and/or ESR monitoring frequency varies by condition; examples provided in policy represent suggested schedules, not exhaustive limits.

Acute Hematogenous Osteomyelitis (AHO)CRP preferred; to confirm diagnosis then every 2–3 days during early therapy, then weekly until normalization or clear trend toward normalization.

Hodgkin lymphomaESR preferred; every 3–6 months for 1–2 years, then every 6–12 months for the next 3 years, then annually thereafter.

Rheumatoid arthritis (example)CRP or ESR; prior to treatment and every 1–3 months during active disease (then less frequently during stable disease).

Large vessel vasculitisCRP and ESR; to confirm diagnosis, every 1–3 months during first year, then every 3–6 months thereafter.

CRP, ESR — frequency not specified

General statementFor many indications the policy lists CRP and/or ESR with frequency noted as 'Not specified' (NS) where no schedule is provided.

Primary care usePolicy notes frequent/regular testing is condition-dependent; when frequency is not specified, clinical judgment and guideline sources inform monitoring.

DocumentationOrders must be linked to a diagnosed or suspected inflammatory condition even when frequency is not specified.

Ordering Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization is required when specified by member benefits or the client's utilization management rules. Verify member eligibility and any prior authorization requirements with BlueCross BlueShield of Tennessee before ordering CRP or ESR testing to avoid claim denials.

Check member benefit plan for prior authorization requirements prior to ordering.
Obtain and include prior authorization number on the claim when required.

Documentation Required

Clinical Indication Documentation Required

Document the clinical indication in the medical record at the time of order. CRP or ESR testing must be tied to a diagnosed or suspected inflammatory condition; when both CRP and ESR are options, CRP is preferred. Do not order ESR for individuals without a diagnosed inflammatory condition or for routine general exams without abnormal findings. Maintain documentation of symptoms, diagnostic impression, and rationale for test selection.

Record the suspected or diagnosed inflammatory condition in the chart (e.g., suspected autoimmune disease, infection, inflammatory bowel disease, vasculitis).
If both CRP and ESR are considered, document why CRP was chosen when available.
Do not order ESR for asymptomatic individuals or during general exams without abnormal findings; such testing does not meet coverage criteria.

Step Therapy

Step Therapy / Test Selection

Adhere to step therapy and test selection preferences: when both CRP and ESR are allowed for an indication, preferentially order CRP (conventional or high-sensitivity as clinically appropriate). Do not perform ESR testing as a substitute when CRP is available and preferred. Follow any payer-specific step therapy edits that require initial use of a preferred test prior to alternate tests.

Prefer CRP over ESR when either is clinically acceptable (conventional CRP or high-sensitivity CRP permitted).
If step therapy edits or test sequencing rules exist in the member's benefit plan, document that preferred testing was attempted or explain medical necessity for deviation.
Failure to follow step therapy/test-preference rules may result in denial of coverage.

Provider Actions and Billing Guidance

Prior Authorization

Affected CPT codes (coverage tied to medical necessity)

CRP and ESR tests identified by CPT codes 85651, 85652, 86140, and 86141 are covered when the medical necessity criteria in this policy are met.

CPT 85651 — Sedimentation rate, erythrocyte; non-automated
CPT 85652 — Sedimentation rate, erythrocyte; automated
CPT 86140 — C-reactive protein
CPT 86141 — C-reactive protein; high sensitivity (hsCRP)

Prior Authorization

No prior authorization mandate specified for CRP or ESR

There are no explicit prior authorization requirements specified in these document sections for CRP or ESR testing.

Step Therapy

CRP is the preferred initial biomarker when either CRP or ESR are permitted

When either CRP or ESR are allowed for an indication, CRP is identified as the preferred initial biomarker.

Step Therapy

No step therapy requirements specified

No step therapy requirements (sequencing or mandatory trials) for CRP or ESR testing are described in these sections.

Documentation Required

Document a diagnosed or suspected inflammatory condition when ordering

Documentation must demonstrate a diagnosed or suspected inflammatory condition to meet coverage; either conventional CRP or hsCRP testing is allowed and CRP is preferred when both options apply.

Clinical record must indicate diagnosed or suspected inflammatory condition tied to the order
Either conventional CRP or hsCRP is acceptable

Documentation Required

Document indication and diagnostic reasoning for CRP/ESR orders (e.g., suspected PJI)

Document the clinical indication and diagnostic reasoning when ordering CRP or ESR, especially for evaluation of suspected prosthetic joint infection or rheumatologic disease where test limitations are noted.

Include rationale when ordering for suspected prosthetic joint infection due to high false-negative rates
Document reasoning when using tests to assess disease activity in autoimmune conditions

Denial Risk

ESR for individuals without a diagnosed inflammatory condition is not covered

Requests for ESR measurement for individuals without a diagnosed inflammatory condition do not meet coverage criteria and will be denied.

Denial Risk

CRP/ESR ordered for routine general exam without abnormalities is not covered

Measurement of CRP or ESR during a general exam without abnormal findings does not meet coverage criteria and will be denied.

Denial Risk

Avoid routine use of multiple inflammatory markers in primary care — limited added accuracy

Use of multiple inflammatory marker tests in primary care is questioned due to low added accuracy; inappropriate or redundant ordering could risk unnecessary testing and potential denial.

Primary care multiple-marker testing has limited additional diagnostic value per cited utilization studies
Avoid redundant inflammatory markers unless clinically justified

Definitions

Definition — C-reactive protein (CRP)

DefinitionC-reactive protein (CRP) is an acute-phase plasma protein produced by the liver and measured in serum as a marker of systemic inflammation.

FormsAvailable as conventional CRP and high-sensitivity CRP (hsCRP); either form is allowed per policy when clinically appropriate.

Clinical useCRP is used to monitor inflammatory activity and is the preferred initial biomarker when either CRP or ESR are permitted for an indication.

Definition — Erythrocyte sedimentation rate (ESR)

DefinitionErythrocyte sedimentation rate (ESR) is a laboratory technique measuring the rate at which red blood cells settle in anticoagulated blood, used as a nonspecific marker of inflammation.

Methodologic noteESR is a simple, established lab technique; measurement methods and modified/alternate methods are described in ICSH recommendations.

LimitationsESR results may be influenced by method and the clinical context; routine tests for some conditions (e.g., periprosthetic joint infection) can show high false-negative rates.

Erythrocyte Sedimentation Rate (ESR) — additional details

Technical descriptionESR measures the rate at which erythrocytes settle over a period (commonly one hour) and serves as a nonspecific marker of inflammation.

Standards and guidanceICSH recommendations describe modified and alternate methods for measuring ESR; clinicians should consider method variability when interpreting results.

Clinical caveatESR may correlate poorly with disease activity in some autoimmune diseases and can be affected by the infecting organism in prosthetic joint infections.

C-reactive protein (CRP) — additional details

PhysiologyCRP is an acute-phase reactant released during the acute inflammatory response and rises in serum in response to tissue injury or disorder.

Assay typesCRP assays include conventional CRP and high-sensitivity CRP (hsCRP); policy allows either when clinically appropriate.

Clinical interpretationCRP is used to monitor inflammation across infectious, rheumatologic, and oncologic conditions, but may misdiagnose chronic or low-grade prosthetic joint infections and should be interpreted with clinical context and guideline sources.

OpenPayer

General Inflammation Testing (CRP and ESR)

Coverage Criteria

Covered Indications and Conditions

Frequency Limits and Monitoring Schedules

Not Covered

Ordering Requirements

Provider Actions and Billing Guidance

Coding

Definitions

Background

85651	Sedimentation rate, erythrocyte; non-automated
85652	Sedimentation rate, erythrocyte; automated
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)